Moderna Cancer Vaccine Data Leak Triggers Stock Rout Despite Positive Results

What’s happening

Moderna's Phase 3 trial data for its custom cancer vaccine leaked before official release, causing the stock to plunge even though the full results—released hours later—showed positive efficacy signals. The vaccine, developed with Merck, demonstrated meaningful survival benefits in aggressive lung cancer patients, but the leak-driven panic selling overshadowed the clinical win.

Market impact

MRNA volatility spiked on the leak, and the sell-first-ask-questions-later reaction highlights how thin conviction is in biotech rallies. Approval appears likely, but the stock's reaction suggests investors are pricing in competitive pressure from other cancer immunotherapies and questions about real-world uptake versus hype.

Broader implications

The incident underscores how information control remains critical in biotech markets, where clinical data can swing valuations by billions. It also signals that even positive cancer vaccine results face skepticism about whether they represent a genuine breakthrough or incremental improvement over existing options.